Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | +9,900.00% | +9,900.00% |
2020 | Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2019 | CI |
2019 | Abattis Bioceuticals Corp. Announces Board Changes | CI |
Sales 2018 | 8.37K 6.14K 485K | Sales 2019 | 357K 262K 20.68M | Capitalization | 8.62M 6.32M 499M |
---|---|---|---|---|---|
Net income 2018 | -78M -57.24M -4.52B | Net income 2019 | -3M -2.2M -174M | EV / Sales 2018 | 5,778 x |
Net cash position 2018 | 9.1M 6.68M 527M | Net cash position 2019 | 2.25M 1.65M 130M | EV / Sales 2019 | 17.8 x |
P/E ratio 2018 |
-0.57
x | P/E ratio 2019 |
-2.8
x | Employees | - |
Yield 2018 * |
-
| Yield 2019 |
-
| Free-Float | 99.64% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | - | 31/03/19 | |
Patrick Mitchell
COO | Chief Operating Officer | - | 31/10/18 |
Jonathan Danieli
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Cedric Wilson
BRD | Director/Board Member | - | 18/10/18 |
Patrick Mitchell
COO | Chief Operating Officer | - | 31/10/18 |
Director of Finance/CFO | - | 31/03/19 |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 476 | |
-.--% | 339M | |
-39.55% | 331M | |
+47.33% | 290M | |
+32.99% | 274M | |
+51.74% | 198M | |
+144.66% | 140M | |
+53.54% | 139M | |
-28.57% | 122M | |
+19.23% | 104M |
- Stock Market
- Equities
- ATTBF Stock